Kopeć Grzegorz, Moertl Deddo, Steiner Sabine, Stępień Ewa, Mikołajczyk Tomasz, Podolec Jakub, Waligóra Marcin, Stępniewski Jakub, Tomkiewicz-Pająk Lidia, Guzik Tomasz, Podolec Piotr
Department of Cardiac and Vascular Diseases of the John Paul II Hospital in Krakow and the Jagiellonian University Collegium Medicum, Krakow, Poland.
PLoS One. 2013 Dec 2;8(12):e82628. doi: 10.1371/journal.pone.0082628. eCollection 2013.
Chronic anticoagulation is a standard of care in idiopathic pulmonary arterial hypertension (IPAH). However, hemostatic abnormalities in this disease remain poorly understood. Therefore, we aimed to study markers of thrombogenesis and fibrinolysis in patients with IPAH.
We studied 27 consecutive patients (67% female) with IPAH aged 50.0 years (IQR: 41.0-65.0) and 16 controls without pulmonary hypertension. Prothrombin fragment 1+2 (F1+2) and thrombin-antithrombin (TAT) complexes were measured to assess thrombogenesis; tissue-type plasminogen activator (tPA) antigen and plasmin-anti-plasmin complex to characterize activation of fibrinolysis; plasminogen activator inhibitor 1 (PAI-1) to measure inhibition of fibrinolysis; and endothelin-1 (ET-1) and interleukin-6 (IL-6) to assess endothelial activation and systemic inflammation, respectively. In addition, in treatment-naive IPAH patients these markers were assessed after 3 months of PAH-specific therapies.
TPA (10.1[6.8-15.8] vs 5.2[3.3-7.3] ng/ml, p<0.001), plasmin-anti-plasmin (91.5[60.3-94.2] vs 55.8[51.1-64.9] ng/ml, p<0.001), IL-6 (4.9[2.5-7.9] vs 2.1[1.3-3.8] pg/ml, p=0.001) and ET-1 (3.7 [3.3-4.5] vs 3.4[3.1-3.5], p= 0.03) were higher in patients with IPAH than in controls. In IPAH patients plasmin-anti-plasmin and tPA correlated positively with IL-6 (r=0.39, p=0.04 and r=0.63, p<0.001, respectively) and ET-1 (r=0.55, p=0.003 and r=0.59, p=0.001, respectively). No correlation was found between tPA or plasmin-anti-plasmin and markers of thrombogenesis. Plasmin-anti-plasmin decreased after 3 months of PAH specific therapy while the other markers remained unchanged.
In the present study we showed that markers of fibrynolysis were elevated in patients with IPAH however we did not find a clear evidence for increased thrombogenesis in this group of patients. Fibrinolysis, inflammation, and endothelial activation were closely interrelated in IPAH.
长期抗凝是特发性肺动脉高压(IPAH)的标准治疗方法。然而,该疾病中的止血异常仍未得到充分理解。因此,我们旨在研究IPAH患者的血栓形成和纤维蛋白溶解标志物。
我们研究了27例连续的IPAH患者(67%为女性),年龄50.0岁(四分位间距:41.0 - 65.0),以及16例无肺动脉高压的对照者。测量凝血酶原片段1 + 2(F1 + 2)和凝血酶 - 抗凝血酶(TAT)复合物以评估血栓形成;测量组织型纤溶酶原激活物(tPA)抗原和纤溶酶 - 抗纤溶酶复合物以表征纤维蛋白溶解的激活;测量纤溶酶原激活物抑制剂1(PAI - 1)以测定纤维蛋白溶解的抑制;测量内皮素 - 1(ET - 1)和白细胞介素 - 6(IL - 6)分别评估内皮激活和全身炎症。此外,在未接受过治疗的IPAH患者中,在进行3个月的PAH特异性治疗后评估这些标志物。
IPAH患者的tPA(10.1[6.8 - 15.8]对5.2[3.3 - 7.3] ng/ml,p < 0.001)、纤溶酶 - 抗纤溶酶(91.5[60.3 - 94.2]对55.8[51.1 - 64.9] ng/ml,p < 0.001)、IL - 6(4.9[2.5 - 7.9]对2.1[1.3 - 3.8] pg/ml,p = 0.001)和ET - 1(3.7 [3.3 - 4.5]对3.4[3.1 - 3.5],p = 0.03)高于对照组。在IPAH患者中,纤溶酶 - 抗纤溶酶和tPA分别与IL - 6(r = 0.39,p = 0.04和r = 0.63,p < 0.001)以及ET - 1(r = 0.55,p = 0.003和r = 0.59,p = 0.001)呈正相关。未发现tPA或纤溶酶 - 抗纤溶酶与血栓形成标志物之间存在相关性。PAH特异性治疗3个月后,纤溶酶 - 抗纤溶酶降低,而其他标志物保持不变。
在本研究中,我们表明IPAH患者的纤维蛋白溶解标志物升高,但在该组患者中未发现血栓形成增加的确切证据。在IPAH中,纤维蛋白溶解、炎症和内皮激活密切相关。